Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services. Speaking at an investor conference, CEO Albert Bourla emphasized a constructive relationship with Kennedy and President-elect Trump, reaffirming Pfizer’s commitment to advancing public health policies. The company remains focused on stabilizing investor confidence following recent share price declines.
Trump’s plans to reform pharmacy benefit managers (PBMs) could bring dramatic reductions to patient medicine costs, a move welcomed by Pfizer as it seeks to address pricing concerns. Bourla defended Pfizer’s strategic turnaround amid pressure from investors over acquisitions and underwhelming drug pipeline results. With top-selling drugs nearing patent expiration, Pfizer has launched cost-cutting initiatives and refocused on core businesses to bolster long-term profitability.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.